BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 10770750)

  • 1. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
    Maga G; Ubiali D; Salvetti R; Pregnolato M; Spadari S
    Antimicrob Agents Chemother; 2000 May; 44(5):1186-94. PubMed ID: 10770750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.
    Shaw-Reid CA; Feuston B; Munshi V; Getty K; Krueger J; Hazuda DJ; Parniak MA; Miller MD; Lewis D
    Biochemistry; 2005 Feb; 44(5):1595-606. PubMed ID: 15683243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes.
    DeStefano JJ
    Biochemistry; 2019 Apr; 58(16):2176-2187. PubMed ID: 30900874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.
    Braz VA; Holladay LA; Barkley MD
    Biochemistry; 2010 Jan; 49(3):601-10. PubMed ID: 20039714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.
    Maga G; Hübscher U; Pregnolato M; Ubiali D; Gosselin G; Spadari S
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1192-200. PubMed ID: 11257034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
    Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
    Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA).
    Patel M; McHugh RJ; Cordova BC; Klabe RM; Erickson-Viitanen S; Trainor GL; Ko SS
    Bioorg Med Chem Lett; 1999 Nov; 9(22):3221-4. PubMed ID: 10576692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
    Bastos MM; Costa CCP; Bezerra TC; da Silva FC; Boechat N
    Eur J Med Chem; 2016 Jan; 108():455-465. PubMed ID: 26708112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors.
    King RW; Klabe RM; Reid CD; Erickson-Viitanen SK
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1640-6. PubMed ID: 12019069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus type 1 reverse transcriptase. 3'-Azidodeoxythymidine 5'-triphosphate inhibition indicates two-step binding for template-primer.
    Jaju M; Beard WA; Wilson SH
    J Biol Chem; 1995 Apr; 270(17):9740-7. PubMed ID: 7537269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
    Ren J; Milton J; Weaver KL; Short SA; Stuart DI; Stammers DK
    Structure; 2000 Oct; 8(10):1089-94. PubMed ID: 11080630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.
    Barnard JP; Huber KD; Sluis-Cremer N
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
    Gawali R; Trivedi J; Bhansali S; Bhosale R; Sarkar D; Mitra D
    Eur J Med Chem; 2018 Sep; 157():310-319. PubMed ID: 30099253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
    Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
    J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial selective inhibition of HIV-1 reverse transcriptase and human DNA polymerases γ and β by thiated 3'-fluorothymidine analogue 5'-triphosphates.
    Wińska P; Miazga A; Poznański J; Kulikowski T
    Antiviral Res; 2010 Nov; 88(2):176-81. PubMed ID: 20739003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3'-azido-3'-deoxythymidine with nonnucleoside inhibitors.
    Cruchaga C; Odriozola L; Andréola M; Tarrago-Litvak L; Martínez-Irujo JJ
    Biochemistry; 2005 Mar; 44(9):3535-46. PubMed ID: 15736963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors.
    Patel M; Ko SS; McHugh RJ; Markwalder JA; Srivastava AS; Cordova BC; Klabe RM; Erickson-Viitanen S; Trainor GL; Seitz SP
    Bioorg Med Chem Lett; 1999 Oct; 9(19):2805-10. PubMed ID: 10522695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.